PATENT CLAIM ANALYSIS

Application Number: 15898258
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2019-02
Patent Classification: ["514", "263400"]

Abstract:
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity (e.g., a condition, disease or disorder associated with an insufficient immune response) that contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

Claim (Index 19):
A method for modulating NLRP3 activity, the method comprising contacting NLRP3 with a compound as claimed in  claim 1 .

Metadata:
- Claim Count in Document: 1.0
- Percentile: 88.0
- Lexical Diversity: 1.95588
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16093990', '16094000', '12813148', '15016841', '14982131']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7581548940577454
- 35 USC 102 Novelty (BERT): 0.5291473621933512
- Combined Prediction Score: 0.735254140871306
- Mean Citation Score: 263.79211200000003
- Max Citation Score: 286.65015
- Similarity Product: 124.45771697159708

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test